Zacks Research Has Positive View of OPKO Health Q3 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Equities researchers at Zacks Research increased their Q3 2026 earnings estimates for OPKO Health in a research report issued on Monday, August 17th. Zacks Research analyst Team now expects that the biotechnology company will earn ($0.06) per share for the quarter, up from their previous estimate of ($0.07). The consensus estimate for OPKO Health’s current full-year earnings is ($0.24) per share. Zacks Research also issued estimates for OPKO Health’s FY2026 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.07) EPS, FY2027 earnings at ($0.28) EPS, Q1 2028 earnings at ($0.06) EPS, Q2 2028 earnings at ($0.06) EPS and FY2028 earnings at ($0.23) EPS.

OPK has been the topic of several other research reports. Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, August 13th. HC Wainwright reissued a “buy” rating on shares of OPKO Health in a research report on Wednesday, July 29th. Finally, Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $1.55.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.36 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.35 and a quick ratio of 2.93. OPKO Health has a 1-year low of $0.98 and a 1-year high of $1.73. The firm has a market capitalization of $1.02 billion, a P/E ratio of -15.11 and a beta of 1.51. The business’s 50-day simple moving average is $1.37 and its 200-day simple moving average is $1.27.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.07. The business had revenue of $163.58 million for the quarter, compared to analyst estimates of $131.23 million. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period last year, the company posted ($0.19) EPS.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of OPK. OP Asset Management Ltd bought a new stake in shares of OPKO Health in the 1st quarter worth about $1,257,000. First Trust Advisors LP bought a new position in shares of OPKO Health during the first quarter worth about $570,000. UBS Group AG grew its stake in OPKO Health by 12.1% in the fourth quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock worth $6,745,000 after purchasing an additional 577,248 shares in the last quarter. Comerica Bank raised its stake in OPKO Health by 7.1% during the fourth quarter. Comerica Bank now owns 120,000 shares of the biotechnology company’s stock valued at $151,000 after buying an additional 8,000 shares in the last quarter. Finally, State of Wyoming bought a new position in OPKO Health during the 1st quarter worth approximately $190,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.